Cortagen Research Overview

Background and Classification

Cortagen belongs to the family of bioregulatory tetrapeptides developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology — the same research tradition responsible for Epithalon (Ala-Glu-Asp-Gly, pineal-derived), Pinealon (Ala-Glu-Asp, pineal-derived), and Vilon (Lys-Glu, immune-derived). Each member of this tetrapeptide family shares the Ala-Glu-Asp core sequence with tissue-specific C-terminal extensions that confer distinct tissue selectivity through proposed differences in chromatin binding geometry and gene promoter interactions.

Cortagen's four-amino acid sequence (Ala-Glu-Asp-Pro, abbreviated AEDP) was identified as the shortest biologically active fragment of cerebral cortex polypeptide extracts demonstrating measureable effects on neuronal gene expression and cellular protection. The proline residue at position 4 differentiates Cortagen from Pinealon (which terminates at Asp) and from Epithalon (which has Gly at position 4) — a structural distinction proposed by Khavinson's group to underlie Cortagen's preferential activity in cortical vs. pineal tissue.

• Sequence: Ala-Glu-Asp-Pro (AEDP)
• Molecular Weight: ~414 Da
• Source Tissue: Cerebral cortex (parent polypeptide extract)
• Core Sequence Shared With: Epithalon (AED-Gly); Pinealon (AED)
• Administration Routes: Subcutaneous, intranasal (research)
• Primary Research Focus: Neuroprotection, cognitive aging, retinal health

The Khavinson Bioregulatory Peptide Family

• Peptide: Epithalon — Sequence: Ala-Glu-Asp-Gly — Source Tissue: Pineal gland — Primary Research Target: Telomerase; systemic aging; longevity — Distinguishing Feature: Telomere elongation; broadest anti-aging evidence
• Peptide: Pinealon — Sequence: Ala-Glu-Asp — Source Tissue: Pineal gland — Primary Research Target: CNS/retinal neuroprotection; circadian — Distinguishing Feature: Smallest; intranasal CNS delivery potential
• Peptide: Cortagen — Sequence: Ala-Glu-Asp-Pro — Source Tissue: Cerebral cortex — Primary Research Target: Cortical neuroprotection; cognitive aging — Distinguishing Feature: Pro residue; cortex-targeted tissue selectivity
• Peptide: Vilon — Sequence: Lys-Glu — Source Tissue: Thymus/immune — Primary Research Target: Immune regulation; T-cell function — Distinguishing Feature: Dipeptide; immune tissue origin
• Peptide: Thymogen — Sequence: Glu-Trp — Source Tissue: Thymus — Primary Research Target: T-cell differentiation; IL-2 — Distinguishing Feature: Approved in Russia; longest clinical use

Mechanism of Action

Cortagen's proposed mechanism follows the model advanced by Khavinson for all tetrapeptides in this series: direct nuclear entry and peptide-DNA interaction that modulates chromatin structure and gene expression at specific genomic loci. Molecular modelling studies from Khavinson's group predict that Cortagen's AEDP sequence forms specific non-covalent interactions with double-stranded DNA — particularly with promoter regions of genes involved in neuronal survival, antioxidant defence, and neurotrophic factor production in cortical cells.

The functional consequence of these proposed chromatin interactions in cortical neurons includes: upregulation of BDNF and NGF expression, reduction of pro-apoptotic gene transcription (Bax, caspase-3), enhancement of antioxidant enzyme expression (SOD1, catalase), and suppression of NF-κB–driven neuroinflammatory gene programmes. These downstream effects collectively constitute the neuroprotective profile documented across Cortagen's preclinical research literature.

It is important to acknowledge that the peptide-DNA interaction model — while supported by molecular modelling and some biochemical evidence from Khavinson's group — remains more mechanistically hypothesis than established fact. No crystallographic structures of Cortagen-DNA complexes have been published, and independent mechanistic validation is limited. The functional research findings (neuroprotection, gene expression changes) are more consistently documented than their proposed molecular basis.

Research Domains

Cortical NeuroprotectionReduces neuronal apoptosis in oxidative stress and ischaemia models. Upregulates Bcl-2 and downregulates Bax. Studied in cerebral ischaemia and excitotoxicity models in rodents. Cognitive AgingImproves spatial learning and memory in aged rodent cohorts. Increases hippocampal BDNF and synaptic density markers. Associated with reduction of age-related neuroinflammatory gene expression. Retinal NeuroprotectionProtects retinal ganglion cells and photoreceptors in light-induced and ischaemic models. Studied in combination with Pinealon for retinal degeneration research — complementary rather than overlapping effects proposed. Antioxidant DefenceUpregulates SOD1 and catalase in cortical tissue. Reduces lipid peroxidation and 8-OHdG (oxidative DNA damage) markers in aged brain tissue. Consistent with Khavinson tetrapeptide class antioxidant profile. NeuroinflammationReduces microglial activation markers in cortical injury models. Downregulates IL-1β and TNF-α in LPS-challenged neuronal cultures. NF-κB pathway suppression proposed as mechanism. Epigenetic ModulationProposed histone acetylation changes at specific neuronal gene loci. DNA methylation pattern normalisation toward younger phenotypes in aged cortical cell cultures in Khavinson laboratory studies.

Neuroprotection Research

The most extensively documented application of Cortagen concerns neuroprotection against cortical injury — specifically the attenuation of neuronal death following ischaemic and oxidative insults. In rodent cerebral ischaemia models (middle cerebral artery occlusion and global ischaemia), subcutaneous or intraperitoneal Cortagen administration significantly reduces infarct volume, decreases TUNEL-positive (apoptotic) neuron counts in the peri-infarct zone, and improves neurological scoring at 24–72 hours post-injury compared to vehicle controls. These findings are mechanistically consistent with Cortagen's proposed upregulation of Bcl-2 family anti-apoptotic proteins and reduction of cytochrome c release from stressed mitochondria.

In oxidative stress models using hydrogen peroxide or rotenone-challenged cortical neuron cultures, Cortagen pre-treatment maintains higher cell viability, lower reactive oxygen species accumulation, and better preserved mitochondrial membrane potential compared to untreated controls — providing in vitro mechanistic corroboration for the in vivo neuroprotection findings.

Cognitive Aging Research

Cortagen's effects on cognitive function in aged rodents parallel those documented for Pinealon and Epithalon, but with a pronounced cortical focus. In behavioural studies using naturally aged Wistar rats (24–28 months), Cortagen administered as repeated subcutaneous courses improves performance on spatial memory tasks (Morris water maze probe trial, radial arm maze accuracy) compared to untreated aged controls — with improvements approaching those of younger adult comparison groups in some experimental series.

Histologically, Cortagen-treated aged brains show increased dendritic spine density in cortical layers II/III, higher BDNF immunoreactivity in cortical pyramidal neurons, and reduced age-related microglial activation — all consistent with a combined neurotrophic and anti-neuroinflammatory mechanism supporting synaptic preservation and new synapse formation in aged cortical tissue.

Cortagen + Pinealon in Research Stacks > > Within the Khavinson bioregulatory peptide research framework, Cortagen and Pinealon are frequently studied as complementary compounds — Cortagen targeting cortical neuronal populations and Pinealon targeting pineal, retinal, and broader diencephalic circuits. The mechanistic rationale for combining them is that they address different but overlapping aspects of CNS aging: Cortagen provides cortex-directed gene expression normalisation, while Pinealon addresses circadian disruption, pineal melatonin decline, and retinal protection. No direct combination RCT has been published, but Khavinson's group has reported additive benefits in aged animal models.

Retinal Research

Despite its cerebral cortex origin, Cortagen demonstrates documented retinal protective effects in light-induced and ischaemic retinal models — an apparent anomaly explained by the shared embryological origin of the retina and diencephalon, and the significant overlap in gene expression programmes between retinal and cortical neurons. In rd mice (inherited retinal degeneration), combined Cortagen and Pinealon administration slows photoreceptor loss more effectively than either compound alone, suggesting complementary rather than redundant mechanisms — consistent with the hypothesis that Cortagen addresses cortical gene regulatory programmes in retinal neurons while Pinealon addresses pineal-melatonin axis effects.

Stability and Research Handling

As a tetrapeptide of approximately 414 Da, Cortagen is among the smallest and most physically stable compounds in the research peptide class. Excellent aqueous solubility at physiological pH, easy reconstitution in bacteriostatic water, and minimal susceptibility to mechanical degradation make it straightforward to handle. Lyophilised Cortagen is stable at −20°C for 24+ months. Reconstituted solutions at 2–8°C remain stable for 4–6 weeks in bacteriostatic water. Small-molecule size makes intranasal administration a viable research delivery route for direct CNS targeting — though formal pharmacokinetic data for intranasal Cortagen is limited compared to Pinealon.

Research Use Only. Research Use Only — Disclaimer This document is prepared for laboratory and research reference purposes only. Cortagen is not approved by the FDA or any Western regulatory agency for human therapeutic use. Evidence originates primarily from the St. Petersburg Institute of Bioregulation with limited independent replication. This content does not constitute medical advice. Researchers must comply with all applicable institutional and jurisdictional regulations.

References

1. Khavinson VKh, et al. "Peptide bioregulators of aging — new data." *Adv Gerontol*. 2011;24(3):400–408.

1. Khavinson V, et al. "Short peptides regulate gene expression in the brain." *Neuro Endocrinol Lett*. 2008;29(3):285–291.

1. Khavinson VKh, Grigoriev EI. "Peptide regulation of brain functions." *Bull Exp Biol Med*. 2005;139(4):371–374.

1. Anisimov VN, Khavinson VK. "Peptide bioregulation of aging: results and prospects." *Biogerontology*. 2010;11(2):139–149.

1. Khavinson VKh, et al. "Retinal effects of the tetrapeptide Ala-Glu-Asp-Pro (Cortagen) in retinitis pigmentosa models." *Neuro Endocrinol Lett*. 2013;34(7):687–692.

1. Sibarov DA, et al. "Cytoprotective effects of epitalon and pinealon in the early postnatal rat brain." *Cell Mol Neurobiol*. 2009;29(6–7):825–831.